Principal Financial Group Inc. Has $8.90 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Principal Financial Group Inc. lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.4% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 285,411 shares of the specialty pharmaceutical company's stock after buying an additional 14,566 shares during the period. Principal Financial Group Inc. owned about 0.52% of Supernus Pharmaceuticals worth $8,899,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of SUPN. Barclays PLC raised its stake in Supernus Pharmaceuticals by 88.3% during the third quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company's stock worth $3,393,000 after acquiring an additional 51,005 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Supernus Pharmaceuticals in the third quarter valued at approximately $791,000. Geode Capital Management LLC grew its stake in shares of Supernus Pharmaceuticals by 5.3% during the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock worth $46,218,000 after buying an additional 74,438 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Supernus Pharmaceuticals by 26.4% during the second quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company's stock worth $45,077,000 after buying an additional 351,900 shares in the last quarter. Finally, Franklin Resources Inc. lifted its stake in shares of Supernus Pharmaceuticals by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company's stock valued at $987,000 after acquiring an additional 2,121 shares during the last quarter.

Analyst Ratings Changes

A number of brokerages recently weighed in on SUPN. Piper Sandler restated a "neutral" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cowen restated a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 15,000 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.98, for a total transaction of $554,700.00. Following the sale, the senior vice president now owns 8,200 shares in the company, valued at $303,236. This represents a 64.66 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the completion of the sale, the chief executive officer now owns 926,172 shares of the company's stock, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,213 shares of company stock valued at $5,660,180. 9.30% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Price Performance

Shares of Supernus Pharmaceuticals stock traded down $0.75 during trading on Tuesday, hitting $36.16. The company's stock had a trading volume of 354,549 shares, compared to its average volume of 436,294. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of 33.79 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $39.37. The stock has a 50-day moving average price of $35.95 and a two-hundred day moving average price of $32.69.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The firm had revenue of $175.70 million for the quarter, compared to analyst estimates of $157.35 million. During the same quarter in the previous year, the company posted ($0.29) EPS. The business's revenue was up 14.2% on a year-over-year basis. On average, equities analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.